266 related articles for article (PubMed ID: 9420037)
1. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide.
Peloquin CA; Jaresko GS; Yong CL; Keung AC; Bulpitt AE; Jelliffe RW
Antimicrob Agents Chemother; 1997 Dec; 41(12):2670-9. PubMed ID: 9420037
[TBL] [Abstract][Full Text] [Related]
2. The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol.
Malone RS; Fish DN; Spiegel DM; Childs JM; Peloquin CA
Am J Respir Crit Care Med; 1999 May; 159(5 Pt 1):1580-4. PubMed ID: 10228130
[TBL] [Abstract][Full Text] [Related]
3. Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis.
Fahimi F; Tabarsi P; Kobarfard F; Bozorg BD; Goodarzi A; Dastan F; Shahsavari N; Emami S; Habibi M; Salamzadeh J
Int J Tuberc Lung Dis; 2013 Dec; 17(12):1602-6. PubMed ID: 24200276
[TBL] [Abstract][Full Text] [Related]
4. Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels.
Agrawal S; Kaur KJ; Singh I; Bhade SR; Kaul CL; Panchagnula R
Int J Pharm; 2002 Feb; 233(1-2):169-77. PubMed ID: 11897421
[TBL] [Abstract][Full Text] [Related]
5. Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus.
Kumar AK; Chandrasekaran V; Kannan T; Murali AL; Lavanya J; Sudha V; Swaminathan S; Ramachandran G
Eur J Clin Pharmacol; 2017 Jan; 73(1):65-70. PubMed ID: 27651240
[TBL] [Abstract][Full Text] [Related]
6. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.
Almeida D; Nuermberger E; Tasneen R; Rosenthal I; Tyagi S; Williams K; Peloquin C; Grosset J
Antimicrob Agents Chemother; 2009 Oct; 53(10):4178-84. PubMed ID: 19620331
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
Mukherjee A; Velpandian T; Singla M; Kanhiya K; Kabra SK; Lodha R
Int J Tuberc Lung Dis; 2016 May; 20(5):666-72. PubMed ID: 27084822
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics, optimised design and sample size determination for rifampicin, isoniazid, ethambutol and pyrazinamide in the mouse.
Chen C; Ortega F; Alameda L; Ferrer S; Simonsson US
Eur J Pharm Sci; 2016 Oct; 93():319-33. PubMed ID: 27473307
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi.
van Oosterhout JJ; Dzinjalamala FK; Dimba A; Waterhouse D; Davies G; Zijlstra EE; Molyneux ME; Molyneux EM; Ward S
Antimicrob Agents Chemother; 2015 Oct; 59(10):6175-80. PubMed ID: 26248378
[TBL] [Abstract][Full Text] [Related]
10. Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers.
Xu J; Jin H; Zhu H; Zheng M; Wang B; Liu C; Chen M; Zhou L; Zhao W; Fu L; Lu Y
Clin Ther; 2013 Feb; 35(2):161-8. PubMed ID: 23410999
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.
Thee S; Seddon JA; Donald PR; Seifart HI; Werely CJ; Hesseling AC; Rosenkranz B; Roll S; Magdorf K; Schaaf HS
Antimicrob Agents Chemother; 2011 Dec; 55(12):5560-7. PubMed ID: 21968358
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients.
Tostmann A; Mtabho CM; Semvua HH; van den Boogaard J; Kibiki GS; Boeree MJ; Aarnoutse RE
Antimicrob Agents Chemother; 2013 Jul; 57(7):3208-13. PubMed ID: 23629715
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.
Ruslami R; Nijland HM; Alisjahbana B; Parwati I; van Crevel R; Aarnoutse RE
Antimicrob Agents Chemother; 2007 Jul; 51(7):2546-51. PubMed ID: 17452486
[TBL] [Abstract][Full Text] [Related]
14. Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations.
Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
Int J Clin Pharmacol Ther; 2002 Oct; 40(10):474-81. PubMed ID: 12395981
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of the First-Line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with or without HIV Coinfection.
Antwi S; Yang H; Enimil A; Sarfo AM; Gillani FS; Ansong D; Dompreh A; Orstin A; Opoku T; Bosomtwe D; Wiesner L; Norman J; Peloquin CA; Kwara A
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855070
[TBL] [Abstract][Full Text] [Related]
16. Food significantly reduces plasma concentrations of first-line anti-tuberculosis drugs.
Kumar AKH; Chandrasekaran V; Kumar AK; Kawaskar M; Lavanya J; Swaminathan S; Ramachandran G
Indian J Med Res; 2017 Apr; 145(4):530-535. PubMed ID: 28862186
[TBL] [Abstract][Full Text] [Related]
17. Bioequivalence of fixed-dose combination Myrin®-P Forte and reference drugs in loose combination.
Wang HF; Wang R; O'Gorman M; Crownover P; Naqvi A; Jafri I
Int J Tuberc Lung Dis; 2013 Dec; 17(12):1596-601. PubMed ID: 24200275
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of First-Line Drugs Among Children With Tuberculosis in Rural Tanzania.
Justine M; Yeconia A; Nicodemu I; Augustino D; Gratz J; Mduma E; Heysell SK; Kivuyo S; Mfinanga S; Peloquin CA; Zagurski T; Kibiki GS; Mmbaga B; Houpt ER; Thomas TA
J Pediatric Infect Dis Soc; 2020 Feb; 9(1):14-20. PubMed ID: 30395239
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India.
Hemanth Kumar AK; Kannan T; Chandrasekaran V; Sudha V; Vijayakumar A; Ramesh K; Lavanya J; Swaminathan S; Ramachandran G
Int J Tuberc Lung Dis; 2016 Sep; 20(9):1236-41. PubMed ID: 27510252
[TBL] [Abstract][Full Text] [Related]
20. Effect of peritoneal dialysis on plasma and peritoneal fluid concentrations of isoniazid, pyrazinamide, and rifampin.
Ahn C; Oh KH; Kim K; Lee KY; Lee JG; Oh MD; Kim Y; Han JS; Kim S; Lee JS; Jang IJ; Shin SG
Perit Dial Int; 2003; 23(4):362-7. PubMed ID: 12968844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
